SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma
Aim: To investigate the impact of polymorphisms in the FPGS, GGH and SLCO1B1 genes on high dose methotrexate (HD-MTX) related toxicity in Chinese patients with non-Hodgkin lymphoma (NHL). Materials & methods: We analyzed FPGS (rs10106), GGH (rs719235, rs10464903, rs12681874), SLCO1B1 (rs4149056) genetic polymorphisms in 105 Chinese patients with NHL treated with HD-MTX. Results: There was a statistically significant impact of the SLCO1B1 rs4149056 polymorphism on hepatotoxicity. Patients with TC and CC genotype had more hepatotoxicity than TT genotype (60 vs 32.94%, p = 0.025). After adjusting for disease stage, dosage, infusion time and therapy method, SLCO1B1 rs4149056 genotype remained significantly associated with hepatotoxicity (p = 0.028). Conclusion: SLCO1B1 rs4149056 genetic variants can affect the HD-MTX-related toxicity in Chinese patients with NHL.
|Keywords||FPGS, gene polymorphism, GGH, methotrexate, non-Hodgkin lymphoma, SLCO1B1, toxicity|
|Persistent URL||dx.doi.org/10.2217/pgs-2017-0110, hdl.handle.net/1765/103111|
Yang, L. (Lin), Wu, H. (Hui), van Gelder, T, Matić, M, Ruan, J.-S. (Jun-Shan), Han, Y. (Yong), & Xie, R.-X. (Rui-Xiang). (2017). SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma. Pharmacogenomics, 18(17), 1557–1562. doi:10.2217/pgs-2017-0110